Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,741 to 2,760 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| IC51 vs Placebo: serious adverse events | 10 of 1,993 6 of 657 | -0.4 points -1.5 to 0.2 | 2,650 | NCT00605085 Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 |
| CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause In-hospital Mortality | 376 of 1,336 393 of 1,312 | -1.8 points -5.3 to 1.6 | 2,648 | NCT01002482 Computerized Glucose Control in Critically Ill Patients |
| CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause 28-day Mortality | 326 of 1,336 328 of 1,312 | -0.6 points -3.9 to 2.7 | 2,648 | NCT01002482 Computerized Glucose Control in Critically Ill Patients |
| CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause 90-day Mortality | 431 of 1,336 447 of 1,312 | -1.8 points -5.4 to 1.8 | 2,648 | NCT01002482 Computerized Glucose Control in Critically Ill Patients |
| CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause Intensive Care Unit Mortality | 302 of 1,336 310 of 1,312 | -1.0 points -4.2 to 2.2 | 2,648 | NCT01002482 Computerized Glucose Control in Critically Ill Patients |
| CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: serious adverse events | 20 of 1,336 6 of 1,312 | 1.0 points 0.3 to 1.9 | 2,648 | NCT01002482 Computerized Glucose Control in Critically Ill Patients |
| Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 79 of 1,325 105 of 1,323 | -2.0 points -3.9 to -0.0 | 2,648 | NCT01858532 Study Of Diabetic Nephropathy With Atrasentan |
| Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 78 of 1,325 88 of 1,323 | -0.8 points -2.6 to 1.1 | 2,648 | NCT01858532 Study Of Diabetic Nephropathy With Atrasentan |
| Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 147 of 1,325 172 of 1,323 | -1.9 points -4.4 to 0.6 | 2,648 | NCT01858532 Study Of Diabetic Nephropathy With Atrasentan |
| Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 72 of 1,325 81 of 1,323 | -0.7 points -2.5 to 1.1 | 2,648 | NCT01858532 Study Of Diabetic Nephropathy With Atrasentan |
| Intensive Control of SBP vs Standard Control of SBP: Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR | 10 of 1,330 12 of 1,316 | -0.2 points -0.9 to 0.6 | 2,646 | NCT01206062 Systolic Blood Pressure Intervention Trial |
| Celecoxib vs Placebo: Number of Participants With Incidence of Second Primary Breast Cancers | 19 of 1,763 12 of 876 | -0.3 points -1.4 to 0.5 | 2,639 | NCT02429427 European Celecoxib Trial in Primary Breast Cancer |
| Celecoxib vs Placebo: deaths from any cause | 203 of 1,763 104 of 876 | -0.4 points -3.1 to 2.2 | 2,639 | NCT02429427 European Celecoxib Trial in Primary Breast Cancer |
| T+OFS vs E+OFS: serious adverse events | 484 of 1,321 496 of 1,317 | -1.0 points -4.7 to 2.7 | 2,638 | NCT00066703 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer |
| Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: deaths from any cause | 5 of 1,317 4 of 1,319 | 0.1 points -0.4 to 0.6 | 2,636 | NCT03060629 A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
| Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: serious adverse events | 49 of 1,317 37 of 1,319 | 0.9 points -0.5 to 2.3 | 2,636 | NCT03060629 A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
| Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With HIV-1 Infection Diagnosed From Enrollment (Baseline) Through Month 24 Post Enrollment | 91 of 1,311 102 of 1,319 | -0.8 points -2.8 to 1.2 | 2,630 | NCT03060629 A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
| Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With HIV-1 Infection Diagnosed From Enrollment (Baseline) Through Month 36 (End of Study) Post Enrollment | 115 of 1,311 127 of 1,319 | -0.9 points -3.1 to 1.4 | 2,630 | NCT03060629 A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
| Dapivirine Vaginal Ring vs Placebo Ring: deaths from any cause | 4 of 1,313 3 of 1,316 | 0.1 points -0.4 to 0.6 | 2,629 | NCT01617096 Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women |
| Dapivirine Vaginal Ring vs Placebo Ring: The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). | 1,237 of 1,313 1,231 of 1,316 | 0.7 points -1.2 to 2.5 | 2,629 | NCT01617096 Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women |
Code
curl "https://conductscience.org/api/comparisons/v1?page=138"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=138
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00605085-sae",
"title": "IC51 vs Placebo: serious adverse events",
"summary": "10 of 1993 against 6 of 657; risk difference -0.4 points, 95% interval -1.5 to 0.2; NCT00605085, Safety and Tolerability of the Japanese Encephalitis Vaccine IC51",
"record": "/library/comparisons/NCT00605085-sae",
"nct_id": "NCT00605085",
"kind": "serious-adverse-events",
"participants": 2650,
"risk_difference": {
"value": -0.004114858626196253,
"lower": -0.015005531671320394,
"upper": 0.002365866764603793
},
"group_1": "10 of 1,993",
"group_2": "6 of 657",
"difference": "-0.4 points",
"interval": "-1.5 to 0.2",
"trial_title": "Safety and Tolerability of the Japanese Encephalitis Vaccine IC51"
},
{
"id": "NCT01002482-778f261c",
"title": "CGAO-based Glucose Control vs Standard-Care Glucose Gontrol: All-cause In-hospital Mortality",
"summary": "376 of 1336 against 393 of 1312; risk difference -1.8 points, 95% interval -5.3 to 1.6; NCT01002482, Computerized Glucose Control in Critically Ill Patients",
"record": "/library/comparisons/NCT01002482-778f261c",
"nct_id": "NCT01002482",
"kind": "outcome",
"participants": 2648,
"risk_difference": {
"value": -0.018105557178326293,
"lower": -0.05263973940891209,
"upper": 0.016463727196489836
},
"group_1": "376 of 1,336",
"group_2": "393 of 1,312",
"difference": "-1.8 points",
"interval": "-5.3 to 1.6",
"trial_title": "Computerized Glucose Control in Critically Ill Patients"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=139",
"request_id": "L3ezhc_sFGE9g8JK"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant